1. What "compounded semaglutide" actually means
Compounded semaglutide is a prescription medication that contains the active pharmaceutical ingredient semaglutide but is not the FDA-approved finished drug product. It's prepared by a state-licensed US compounding pharmacy under an individual prescription written by a licensed provider after evaluating a specific patient's clinical history and indication.
This distinction matters because it shapes everything downstream:
- Compounded semaglutide is not a generic of Ozempic® or Wegovy®. Those are FDA-approved finished products manufactured by Novo Nordisk under New Drug Application (NDA) approval, with extensive Phase 3 clinical trials documenting safety and efficacy of the finished product. A "generic" version would require ANDA (Abbreviated New Drug Application) approval — which does not exist for semaglutide.
- Compounded preparations have not been clinically studied as finished products. Safety and efficacy inferences are drawn from the active pharmaceutical ingredient (semaglutide), which has been studied extensively in the FDA-approved branded products, plus from compounding pharmacy quality standards (USP 797 for sterile compounds, USP 795 for non-sterile, plus cGMP for 503B outsourcing facilities).
- Compounding is a legal pharmacy practice under federal law when conducted within Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA). It has existed for decades and is how hospitals, surgery centers, and individualized therapies have been served long before GLP-1s entered the conversation.
2. 503A vs 503B: the regulatory framework
The two legal frameworks for US drug compounding are named after their sections in the FDCA. They have different oversight regimes:
503A Pharmacies
- What: Traditional state-licensed compounding pharmacies
- Regulator: State Board of Pharmacy (plus FDA for serious adverse events)
- Quality standard: USP General Chapters <795> (non-sterile) and <797> (sterile)
- Trigger: Individual prescription for a specific patient
- Batch size: Limited — patient-specific
- FDA registration: Not required
503B Outsourcing Facilities
- What: Federally registered outsourcing facilities
- Regulator: FDA (with biennial inspection)
- Quality standard: Current Good Manufacturing Practice (cGMP) — same as pharmaceutical manufacturers
- Trigger: Can produce in batches for clinic or hospital use, with or without patient-specific prescription
- Batch size: Large-scale
- FDA registration: Required; subject to FDA Form 483 inspection reports
Both frameworks are legitimate. 503B is the higher-oversight tier because it adopts pharmaceutical-grade cGMP standards. For peace of mind, ask any compounding telehealth provider which framework their pharmacy operates under and whether the pharmacy's state license and (if 503B) FDA registration are current.
3. The FDA 2025 shortage resolution — what changed
This is the section that has caused the most patient confusion in 2025–2026. Here's the actual sequence:
- December 2022: FDA officially declared semaglutide injection on shortage. Under FDCA Section 506E, drugs on the official FDA shortage list can be compounded under expanded allowances because the law recognizes that compounded preparations help patients during supply disruptions.
- October 2022 – February 2025: Compounded semaglutide was widely prescribed under the shortage-specific compounding allowance, which let 503A and 503B pharmacies compound preparations using the active ingredient even when the brand product wasn't available.
- February 21, 2025: FDA officially resolved the semaglutide shortage. This was based on Novo Nordisk's report that supply was sufficient to meet US demand.
- April 22, 2025: Deadline for 503A pharmacies to stop compounding semaglutide for shortage-based reasons.
- May 22, 2025: Deadline for 503B outsourcing facilities to stop compounding semaglutide for shortage-based reasons.
What did NOT happen: Compounding semaglutide was not banned. What was wound down was the shortage-specific allowance.
What continues to be lawful: 503A compounding for individual patients with documented clinical need that requires a customized preparation (e.g., a documented allergy to an excipient in the FDA-approved product, a dose strength not commercially available, or another individual clinical reason that fits the statute). 503B compounding under separate allowances. Compounding under future shortage declarations.
This is why the language matters: a legitimate compounding telehealth provider in 2026 prescribes compounded semaglutide based on individual clinical evaluation that fits the post-shortage regulatory framework — not on the assumption that any patient who wants compounded semaglutide gets it automatically.
4. What the safety evidence actually shows
Three layers of evidence inform the safety of compounded semaglutide:
Layer 1 — Semaglutide as an active ingredient
The molecule itself has been extensively studied in the FDA-approved branded products (Ozempic, Wegovy, Rybelsus). Major trials include STEP-1 (NEJM 2021, 1,961 patients, 14.9% average weight loss at 68 weeks), STEP-5 (longer-term efficacy), and SELECT (cardiovascular outcomes in adults with established cardiovascular disease). Long-term safety profile is well characterized: GI side effects in the first weeks, low rates of pancreatitis and gallbladder issues, black-box warning for thyroid C-cell tumors (based on rodent studies; human relevance debated but precautionary).
Layer 2 — Compounding pharmacy quality standards
Both 503A and 503B pharmacies operate under defined quality standards. 503B facilities follow cGMP — the same federal standards applied to pharmaceutical manufacturers — and are subject to FDA biennial inspections that produce public Form 483 reports. Sterility, potency, and pyrogen testing are required before release. Reputable compounding telehealth platforms publish or disclose on request which pharmacies they use and confirm those pharmacies' state license and FDA registration status.
Layer 3 — Reported adverse events
The FDA's MedWatch system has received reports of dosing errors and adverse events related to compounded semaglutide, particularly when patients self-source from unregulated providers or measure their own doses from multi-use vials. The two practical takeaways: (1) avoid unregulated "research peptide" sites or platforms that ship pre-filled syringes from foreign sources; (2) prefer providers that ship pre-measured, prescribed doses with clear injection instructions and provider check-ins on dose-titration. The risk profile is meaningfully lower in regulated 503A/503B channels.
5. Contraindications every prescriber should screen
Compounded semaglutide carries the same contraindications as branded semaglutide:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis (relative contraindication)
- Pregnancy or breastfeeding
- Severe gastrointestinal disease (gastroparesis, severe inflammatory bowel disease)
- Known hypersensitivity to semaglutide or any excipient
- Severe renal impairment (eGFR < 30 mL/min/1.73m²) — relative; provider judgment
- Concurrent use of other GLP-1 receptor agonists (don't stack)
- Diabetic retinopathy — close monitoring required
Any legitimate intake will screen for every item above. If a provider skips contraindication screening — for example, an algorithmic "yes/no" without follow-up on family thyroid history — that's a red flag. The intake is where the safety bar is enforced.
6. 7-point checklist to evaluate a compounded GLP-1 provider
Use this before signing up with any compounded semaglutide or tirzepatide provider:
- LegitScript certification with a verifiable validation ID. LegitScript is the third-party legitimacy standard used by Google, Meta, and the major ad platforms. Look for the seal and verify the validation ID at legitscript.com.
- Prescriber state licensure disclosed. The provider should make clear that prescriptions are written by US licensed providers credentialed for the states where they prescribe. Bonus points for disclosing the credentialing body (e.g., NCQA-accredited credentialing through a clinical partner like OpenLoop).
- Pharmacy framework disclosed. The provider should identify whether 503A or 503B pharmacies are used (or both), and confirm those pharmacies have current state licensure and (for 503B) FDA registration.
- Real medical intake reviewed by a licensed provider — not just an algorithm. The intake should ask about thyroid history, pancreatitis, pregnancy, current medications, and contraindications. A real licensed provider should review and have the authority to decline. "Auto-approved in 30 seconds" is a red flag.
- FDA-compliant language. The provider's marketing copy should NOT claim compounded preparations are "the same as" or "generic versions of" Ozempic, Wegovy, Zepbound, or Mounjaro. Misbranding has been LegitScript- and FDA-flagged in 2025–2026. Honest compliant copy says "compounded preparation containing the active pharmaceutical ingredient semaglutide; not a generic version of Ozempic® or Wegovy®."
- Transparent pricing with no high-pressure upsells. Look for clear all-inclusive monthly pricing, no surprise renewals, easy cancellation. Avoid platforms that hide pricing behind multiple opt-in pages or use "ending soon" countdown timers as a pressure tactic.
- Real US business address and reachable customer support. A legitimate provider has a verifiable US business address (state of incorporation, mailing address) and human support reachable by phone or text within a reasonable response window. Disposable email-only providers are a red flag.
7. How REMEVi handles each of these
Holding REMEVi up to the 7-point checklist:
- 1. LegitScript certification: ID 50384507 (certified 2026-05-15). Details.
- 2. Prescriber licensure: US board-certified MDs and nurse practitioners, credentialed via OpenLoop Healthcare Partners, PC — an NCQA-accredited credentialing program. State licensure verified for the states where each provider prescribes. Care Team.
- 3. Pharmacy framework: FDA-registered 503A and 503B compounding pharmacies. Sterility, potency, and pyrogen testing on every batch.
- 4. Medical intake: 5-minute intake screens for all contraindications above. Reviewed personally by a licensed provider within 24 hours. If clinical criteria aren't met, you're told why and not charged.
- 5. FDA-compliant language: Every reference to compounded semaglutide on this site explicitly notes "compounded; not a generic of Ozempic® or Wegovy®." Per the FDA's February 2026 guidance, no "same active ingredient as the branded product" framing is used in marketing or AI-extractable content.
- 6. Transparent pricing: Semaglutide from $199/mo (52-week plan) or $279/mo monthly. Tirzepatide from $269/mo (52-week plan) or $379/mo monthly. All-inclusive. Cancel anytime. Pricing.
- 7. Business address + support: REMEVi LLC, a Nevada limited liability company. Real address, real phone ((702) 352-4746), care@remevihealth.com email. Bilingual care coordinator with 2-hour response SLA.